Tiziana life sciences announces ind filed for phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancer

New york, jan. 04, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the investigational new drug (ind) application filing for milciclib in combination with gemcitabine for non-small cell lung cancer (nsclc).
TLSA Ratings Summary
TLSA Quant Ranking